Related Experiment Video
Updated: Jan 15, 2026

09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
18.2K
Standardized antibody purification process development workflow using a novel gravity column-based high throughput
1Downstream Process Development (DSPD), WuXi Biologics, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Journal of Chromatography. A
|October 10, 2025
Summary
A new high-throughput process development (HTPD) method using gravity columns accelerates antibody purification. This HTPD approach significantly reduces timelines and costs for monoclonal antibody development.
Area of Science:
- Biotechnology
- Biopharmaceutical Manufacturing
- Process Development
Background:
- High-throughput process development (HTPD) is crucial for efficient antibody purification.
- Existing methods using microplates or miniature columns have limitations.
- Faster, cost-effective, and material-efficient purification processes are needed.
Purpose of the Study:
- To introduce a novel HTPD method for antibody purification.
- To demonstrate the method's efficiency in developing purification processes for monoclonal antibodies (mAbs).
- To assess the scalability and product quality of the developed purification method.
Main Methods:
- Utilized optimized gravity columns and liquid-handling workstations for HTPD.
- Developed a three-column purification process for mAbs.
- Scaled up the process from laboratory to pilot scale (50 L cell culture fluid).
Main Results:
- A three-column purification process for mAbs was developed in two days.
- The gravity column method yielded product quality comparable to large-scale columns.
- The HTPD method was successfully applied to a challenging bispecific antibody, demonstrating versatility.
Conclusions:
- The novel HTPD method offers enhanced efficiency and reduced timelines for mAb purification.
- The method is scalable and maintains product quality, making it suitable for industrial application.
- This approach improves the versatility of HTPD for complex biomolecules like bispecific antibodies.

